X CLOSE

Another early stage California company in stealth mode has garnered a round of financing. This time it’s a biotech company called Nurix Inc., founded by three University of California, San Francisco and University of California, Berkeley researchers to leverage their drug discovery platform and develop new therapeutics for inflammatory diseases.

With its drug discovery platform, the company was formed to identify and develop inhibitors of the kinase ZAP-70, which has been shown to play a critical function in progression of T-cell-dependent autoimmune diseases like rheumatoid arthritis, lupus, multiple sclerosis and psoriasis, according to an abstract published with the notice of a $300,000 SBIR grant. The company says its focus is on finding leads for new T-cell-specific immunosuppressant drugs.

Advertisement

Formed in 2009 as Kura Therapeutics, the company appears to be led by Tim Kutzkey, a partner at The Column Group, and Mark Goldsmith, a partner at Third Rock. It first raised a $3.1 million round raised last year.

Hear the latest industry news first

Get our daily newsletter or follow us.

Please enter your email below:

By Deanna Pogorelc MedCity News

Deanna Pogorelc is a Cleveland-based reporter who writes obsessively about life science startups across the country, looking to technology transfer offices, startup incubators and investment funds to see what’s next in healthcare. She has a bachelor’s degree in journalism from Ball State University and previously covered business and education for a northeast Indiana newspaper.More posts by Author